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Background: Malaria infection during pregnancy is associated with adverse outcomes in sub-Saharan Africa (SSA).
For this reason, the World Health Organization currently recommends intermittent preventive treatment of malaria
in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) at each scheduled antenatal care (ANC) visit. In Tanzania,
the revised IPTp policy was adopted in 2013 but the level of uptake and its association with pregnancy outcomes
remains unknown.
Methods: A cross-sectional study was conducted among singleton pregnant women who delivered in two selected
health facilities of Geita district, northwestern Tanzania. Self-reported uptake of SP was verified using the ANC card
and was recorded. Placental and peripheral blood was collected for diagnosis of malaria by microscopy and rapid
diagnostic tests (RDTs). Gestational age was estimated based on last menstrual period or Ballard score. Infant birth
weights were recorded within 24 hours of delivery.
Results: Of 431 participants, 167 (38.75%), 134 (31.09%), 104 (24.23%), and 26 (6.03%) reported taking none, one, two,
and≥ three doses of SP during pregnancy, respectively. The uptake of≥ three doses of IPTp-SP among delivering
women at Geita hospital and Katoro health centre was 9.06% and 1.2%, respectively. The overall prevalence of malaria
in pregnancy by RDT, peripheral and placental smears was 19.5%, 29.7% and 37.6% respectively. The prevalence of
placental parasitaemia was higher for women who delivered at Katoro Health Centre (41.57%) than those who delivered
at Geita hospital (35.09%). The uptake of≥ three doses of SP was associated with reduced odds of having placental
malaria (adjusted odds ratio (AOR) = 0.31, p = 0.039) compared to < three doses. Women with placental parasitaemia
were five times more likely to have delivered pre-term (AOR = 4.67, p = 0.002) and had lower mean birth weight infants
than their uninfected counterparts (mean difference = 82 g, p = 0.039).
Conclusions: The uptake of≥ three doses of IPTp-SP is low in the present study area. Placental parasitaemia is prevalent
and is associated with adverse birth outcomes. Receipt of≥ three doses of IPTp-SP reduced the odds of placental
parasitaemia. Thus, increased efforts towards scale-up and continuous evaluation of IPTp-SP efficacy is recommended.
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Of the 125 million pregnant women who are at risk of
Plasmodium falciparum infection each year, 30 million
are from SSA [1]. Plasmodium falciparum malaria infec-
tion during pregnancy presents significant risks for the
pregnant woman, the developing foetus and the new-
born infant. The negative consequences associated with
malaria in pregnancy include: severe malaria, severe
anaemia, pre-term delivery, maternal death, and pla-
cental malaria [2-4]. Placental malaria is linked to intra-
uterine growth restriction, stillbirth, and delivery of low
birth weight (LBW) infants [5,6]. Pre-term delivery and
LBW are the risk factors for neonatal and infant deaths
[7]. In Africa where malaria is endemic, malaria-causing
LBW kills between 62,000 and 363,000 new-borns every
year [8,9]. In Tanzania, 93% of the population is at risk
of malaria infection. Plasmodium falciparum malaria is
responsible for up to 125,000 deaths in Tanzania, of
which, 70,000-80,000 deaths occur in children who are
under five years old [10]. The disease accounts for at
least one fifth of all maternal deaths in Tanzania [11].
To prevent the effects of P. falciparum malaria during
pregnancy, the World Health Organization (WHO) cur-
rently recommends intermittent preventive treatment
of malaria in pregnancy (IPTp) using sulphadoxine-
pyrimethamine (SP) at each scheduled antenatal care
(ANC) visit after the first trimester [12]. In SSA, the
effectiveness of IPTp-SP in preventing malaria-related
adverse pregnancy outcomes is well established [13-15].
Despite the widespread adoption of IPTp in malaria-
endemic countries in Africa, the coverage of recom-
mended doses of IPTp-SP remains elusive [16]. In 2012,
the median coverage of at least one, two and three doses
of SP during pregnancy in SSA was 64% (range 25-85%),
38% (range 10-64%), and 23% (range 2-44%), respectively
[17]. In Tanzania, the coverage of at least one and two
doses as per Tanzania HIV/AIDS Malaria Indictor Survey
2011/12 was 60% and 32%, respectively [18]. In addition,
the widespread SP resistance caused by P. falciparum
dihydrofolate reductase/dihydropteroate synthase (pfdhfr/
pfdhps) quintuple or sextuple mutations [19,20] is likely to
affect the efficacy of SP in East Africa, including Tanzania.
However, a recent systematic review and meta-analysis
showed beneficial effects of three or more doses of SP dur-
ing pregnancy in prevention of malaria-related adverse out-
comes, even in areas with moderate to high SP resistance
[21]. The new IPTp regimen has recently been imple-
mented in Tanzania; thus the level of uptake and its associ-
ation with pregnancy outcomes remains unknown in
various regions of the country. The purpose of the present
study was to determine the uptake of SP among pregnant
women based on the revised recommendations, and to
evaluate its association with adverse pregnancy outcomes,
including placental malaria, pre-term delivery and LBW.Methods
Study sites, design, participants and selection
This analytical cross-sectional study was conducted from
May to June 2014 in delivery units at Geita district hos-
pital and Katoro health centre, north-western Tanzania.
Geita hospital is located within the capital city of Geita
region (urban) while Katoro rural health centre is located
45 kilometre from Geita city (peri-urban). The inhabitants
of Geita district are predominantly subsistence farmers
and belong to the Sukuma and Zinza ethnic groups. Their
main activities are farming, livestock keeping, small busi-
ness, fishing, and mining. Malaria is highly endemic in this
area with highest transmission occurring between March
and June. Lake Zone has more than 80% prevalence of
the pfdhfr/pfdhps quintuple mutant of IRNGE haplotype
associated with SP resistance [22]. Pregnant women aged
15–49 years delivering at Geita district hospital or Katoro
health centre were assessed for enrolment. Women were
enrolled in our study if they fulfilled the following inclusion
criteria: 1) singleton pregnancy; 2) seronegative for HIV; 3)
absence of reported antimalarial treatment other than SP
in the previous one month; and, 4) consented to be in-
cluded in the study. Convenience sampling was used to re-
cruit pregnant women who met the inclusion criteria and
consented to participate in the study. Study participants
were enrolled until the required sample size was reached.
Sample size
The two-proportion sample size formula without the cor-
rection factor by Fleiss [23] at 90% power level and 5%
level of significance was used to estimate the required sam-
ple size. A minimum sample size of 426 women was calcu-
lated by considering the previous study that reported the
proportion of women with placental malaria among ≥ three
doses of SP group of 8% and that among < three doses of
SP group of 17% [13]. A total of 431 delivering women in
selected health facilities were recruited into the study.
Data collection
Demographic and obstetric information
Information was collected using an interviewer-
administered structured questionnaire. The question-
naire collected socio-demographic information such as
maternal age, marital status, education, and occupation.
Also, obstetric history on parity, timing and frequency of
ANC visits were collected. ANC cards were examined and
information on the use of SP during pregnancy, number
of doses taken, gestational age at first and subsequent SP
doses, and the time lapse from the last dose to delivery
were recorded. The ANC card also provided information
on gestational age at first ANC clinic visit and frequency
of ANC clinic attendance.
Birth weights of new-borns were measured within
24 hours of birth using SECA weighing scales (Vogel &
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age was estimated based on last normal menstrual pe-
riod, and if uncertain and no early ultrasound scans
available, the new Ballard score maturational assessment
[24] was done within 24 hours of delivery by trained
midwives.
Blood sample collection, processing and examination of
malaria parasites and antigens
Malaria infection was screened in both placental and ma-
ternal peripheral blood samples by microscopy and rapid
diagnostic tests (RDTs). Two mL of maternal peripheral
venous blood were collected immediately after delivery,
from which a thick blood smear was prepared and malaria
RDT was done. Placental blood was collected using the
procedures described elsewhere [25], for thick smear
preparation. Both peripheral and placental blood samples
were collected into the vacuum tubes containing ethylene
diamine tetra acetic acid (EDTA) anticoagulants and
smears were prepared within one hour after collection.
Maternal blood samples were evaluated by histidine rich
protein II (HRP II) and parasite lactate dehydrogenase
(pLDH) antigen-based malaria RDTs (Standard Diagnostic
Inc, South Korea). RDTs were performed according to the
manufacturer’s instructions and examined after 15 min
following addition of four drops of the wash buffer.
Thick smears prepared from peripheral and placental
blood samples were fixed with absolute ethanol and
stained with 10% Giemsa for 30 min [26]. Slides were ex-
amined by two independent laboratory technicians using
light microscopy x 100 objectives under oil immersion for
the presence of any malaria parasites stages. To minimize
observation bias, the laboratory technicians reading the
placental and peripheral smears were blinded to results of
RDTs. Discordant results were given a third reading by a
microbiologist blinded to the results of the first two rea-
dings, the result of which was considered final. A thick
film was considered positive when any stage of malaria
parasites were detected. At least 100 high power fields
were examined before a thick smear was declared nega-
tive. Malaria parasites were counted against 500 leucocytes
and parasite densities expressed per μl blood, assuming a
white blood cell count of 8,000/μl blood. The parasite
density (parasite/μL of blood) was then calculated as fol-
lows: Parasite density = (number of parasites counted/
leukocytes counted) × white blood cell count/μL blood [27].
Definitions
IPTp-SP was defined as provision of treatment doses of
SP to asymptomatic pregnant women living in malaria-
endemic regions, regardless of malaria parasitaemia status.
In areas of stable malaria transmission, WHO currently
recommends IPTp-SP for all pregnant women at each
scheduled ANC visit provided that each dose is taken fourweeks apart from the other and continuing up to the time
of delivery. Paucigravidae was defined as women in their
first and second pregnancies and multigravidae referred to
women with three or more pregnancies. Placental malaria
was defined as direct detection of asexual stage of malaria
parasites in placental thick smears regardless of Plas-
modium species. Birth weights below 2,500 g measured
within 24 hours of birth was regarded as LBW. Pre-term
delivery was defined as delivery of an infant before
37 weeks gestational age.
Data analysis
Data collected were double-entered and cleaned using
Epi-Data version 3.1 (CDC, Atlanta, GA, USA), and then
exported to STATA version 12.0 (Stata Corp, College
Station, TX, USA) for analysis. The primary exposure vari-
able of interest was IPTp-SP usage, categorized into < three
doses versus ≥ three doses of IPTp. Data were summarized
in the form of proportions and frequency tables for cate-
gorical variables. Means with their respective standard de-
viations were used to summarize continuous variables.
Bivariate logistic regression analyses were performed to
determine the presence or absence of association between
SP usage and placental malaria. All explanatory variables
with p <0.20 in the bivariate analysis, were included in the
multivariable analysis to further examine the association
between IPTp-SP use and placental malaria. Secondary
analyses were done to determine association between pla-
cental malaria and birth outcomes (birth weight and pre-
term delivery) using logistic and linear regression analyses.
Adjusted odds ratio (AOR), regression coefficients and
95% confidence intervals were reported. The level of sig-
nificance was considered at 5%.
Ethical considerations
Written informed consent for study participation was
obtained from all participants aged 18 years and above.
For women aged below 18 years, informed assent was
obtained and their husbands, mothers or mother in-
laws provided informed consents. The study was ap-
proved by the Joint Catholic University of Health and
Allied Sciences (CUHAS)/Bugando Medical Centre (BMC)
Research Ethical Committee (Certificate No. CREC/016/
2014) and local authorities. Women found to have malaria
at delivery were treated with the anti-malarial treatment
protocol in line with national guidelines.
Results
Study participant characteristics
A total of 431 women were enrolled out of 1,701 total
deliveries in Geita district hospital and Katoro rural
health centre from May-June 2014. The demographic
characteristics of the 431 women with singleton deli-
veries who participated in the present study are shown
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years, and the majority (77.49%) were aged above 20 years.
Nearly two-thirds (61.48%) of the women delivered at
Geita district hospital. Of 431 delivering women, one-
third had previously visited at least four or more antenatal
care visits. Of all the study participants, 227 (52.67%) were
in their first and second pregnancies. Majority (82.83%) of
women were married, 85.53% had primary level or no for-
mal education and 85.85% were peasants and/or keeping
livestock.
Uptake of IPTp-SP
Of 431 women delivering at selected health facilities, 26
(6.03%) received three or more doses of SP, 104 (24.13%)
received two doses, 134 (31.09%) received one dose and
167 (38.74%) received no SP at all. Of 265 women who de-
livered at Geita hospital, 38 (14.34%) did not receive any
dose of SP, 109 (41.13%) received one dose, 94 (35.47%)
received two doses and only 24 (9.06%) took three or
more doses of SP during pregnancy. Among 166 deli-
vering women at Katoro health centre, 129 (77.71%) did
not receive any dose, 25 (15.06%) received one dose,Table 1 Characteristics of 431 women with singleton










Geita Hospital 265 (61.48)
Katoro HC 166 (38.52)
Gravidity
Paucigravidae (G1/G2) 227 (52.67)





Peasants/livestock keeping 370 (85.85)
Employed/business 61 (14.15)
ANC visits
<4 visits 276 (64.04)
≥4 visits 155 (35.96)
ANC = antenatal care, SP = sulphadoxine-pyrimethamine, G1 = primigravidae,
G2 = secundigravidae, G3+ = gravida 3 and above, HC = health centre,
IPTp-SP = intermittent preventive treatment of malaria during pregnancy with SP.10 (6.02%) received two doses and only 2 (1.2%) received
the recommended three or more doses of IPTp-SP. On
bivariate logistic regression analysis (Table 2), the uptake
of ≥3 doses of SP during pregnancy was significantly
associated with ≥ four ANC visits attended by the women
(OR = 4.41, 95% CI, 1.87-10.42, p = 0.001), higher level of
education (OR = 4.22, 95% CI, 1.85-9.62, p = 0.001), area
of residence in urban setting, (OR = 8.20, 95% CI, 1.90-
34.48, p = 0.005), and being employed or doing business
(OR = 4.35, 95% CI, 1.85-10.10, p = 0.001). There was no
significant difference in the uptake of SP during pregnancy
between age groups, marital status and gravidity. In multi-
variable analysis (Table 2), women delivering at Geita hos-
pital (AOR = 8.33, p = 0.007) and attendance of four or
more ANC visits (AOR = 4.35, p = 0.001) were associated
with uptake of ≥3 doses of IPTp-SP.
Prevalence of malaria in pregnancy and birth outcomes
The overall prevalence of malaria in pregnancy based on
malaria RDT was 19.49% (95% CI, 15.73-23.24), all of
which occurred among women who received < three
doses of SP. The prevalence of malaria in pregnancy by
RDT among delivering women at Geita hospital and
Katoro health centre was 13.58% and 28.92% respec-
tively. The sensitivity of RDT in detection of specific
parasite proteins was very low. Over half, 60.94% and
66.05% of women with peripheral and placental positive
smears respectively had negative blood by RDT. Malaria
Plasmodium species based on RDT were P. falciparum,
61.90% (n = 52), non-falciparum malaria parasites, 5.95%
(n = 5) and mixed infections, 32.14% (n = 27).
The overall prevalence of peripheral malaria by micros-
copy was 29.70% (95% CI, 25.37-34.03). The prevalence of
peripheral malaria by smear among delivering women at
Geita hospital and Katoro health centre was 25.28% and
36.75% respectively. The overall geometric mean parasite
density (GMPD) of peripheral parasitaemia was 167.75
(95% CI, 141.52-198.85) parasites/μL. Of 128 delivering
women with peripheral parasitaemia, 73 (57.03%) had
parasite density <100 parasites/μL.
The overall prevalence of placental malaria by micros-
copy was 37.60% (95% CI, 33.00-42.18). The prevalence of
placental malaria by microscopy among delivering women
at Geita hospital and Katoro health centre was 35.09% and
41.57% respectively. The overall GMPD (95% CI) of
the placenta was 144.31 (126.25-164.95) parasites/μL.
Among 162 delivering women with placental parasitaemia,
98 (60.49%) had parasite density <100 parasites/μL.
Of 431 delivering women at selected health facilities, 58
(13.46%) had pre-term deliveries. Of these, 54 (93.10%)
had gestational age 34–36 weeks at delivery. The pre-
valence of pre-term delivery among women delivering
at Geita hospital and Katoro health centre was 9.43%
(n = 25) and 19.88% (n = 33) respectively. Of 431 women
Table 2 Factors associated with uptake of three or more doses of IPTp-SP among delivering women
Variable IPTp-SP uptake COR (95% CI) P-value AOR (95% CI) P-value
N ≥3 doses, n (%)
Maternal age
<20 years 97 3 (3.09) Reference Reference
≥20 years 334 23 (6.89) 2.33 (0.68-7.87) 0.179 2.33 (0.63-9.09) 0.203
Marital status
Single 74 7 (9.49) 1.86 (0.75-4.60) 0.180 2.37 (0.84-6.67) 0.103
Married 357 19 (5.32) Reference Reference
Health facility
Katoro HC 166 2 (1.20) Reference Reference
Geita hospital 265 24 (9.06) 8.20 (1.90-34.48) 0.005 8.33 (1.79-33.33) 0.007
Level of education
None/Primary 360 15 (4.17) Reference Reference
Secondary/Higher 71 11 (15.49) 4.22 (1.85-9.62) 0.001 1.69 (0.66-4.35) 0.275
Occupation
Peasants 370 16 (4.32) Reference Reference
Employed/business 61 10 (16.39) 4.35 (1.85-10.10) 0.001 1.85 (0.70-5.00) 0.214
ANC visits
<4 visits 276 8 (2.90) Reference Reference
≥4 visits 155 18 (11.61) 4.41 (1.87-10.42) 0.001 4.35 (1.79-11.11) 0.001
ANC: antenatal care; AOR: adjusted odds ratio; COR: crude odds ratio; IPTp-SP: intermittent preventive treatment of malaria in pregnancy with sulphadoxine-
pyrimethamine; Significant p-values are presented in bold.
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had low birth weight babies. Of 10 infants with LBW, 8
(80%) were born prematurely. The prevalence of LBW
among delivering women at Geita hospital and Katoro
health centre was 2.64% (n = 7) and 1.81% (n = 3)
respectively.
Factors influencing the placental parasite density
On bivariate analysis, young women <20 years (p = 0.049),
delivering at Katoro rural health centre (p <0.001), having
low level of education (p = 0.014) and being a peasant or
keeping livestock (p = 0.034) had high placental parasite
density. However, after adjusting for other covariates,
women delivering at Katoro rural health centre (p <0.001)
and non-use of any type of bed net (p = 0.030) remained
independently associated with placental parasite density.
Receiving less than three doses of IPTp-SP was a per-
fect predictor of >100 parasites/μl of placental samples
(Table 3).
Factors influencing the prevalence of malaria in
pregnancy using RDT
Factors associated with prevalence of malaria in preg-
nancy by RDT are summarized in Table 4. Bivariate lo-
gistic regression analysis revealed that receipt of three or
more doses of IPTp-SP was associated with negativeRDT. Maternal age younger than 20 years (OR = 1.87,
p = 0.020), women from peri-urban area (OR = 2.59,
p <0.001), paucigravidae (OR = 2.06, p = 0.005), women
with low level of education (OR = 4.79, p = 0.003), pea-
sants (OR = 3.04, p = 0.021) were associated with
increased odds of malaria in pregnancy using RDT in
crude analysis. In multivariable analysis while controlling
for possible confounders, women delivering at Katoro
rural health centre (AOR = 2.86, p <0.001) and those
with low level of education (AOR = 3.51, p = 0.023)
remained significantly associated with malaria in preg-
nancy based on RDT.
Uptake of IPTp-SP and peripheral malaria by microscopy
at delivery
The association between IPTp-SP use and peripheral
malaria by microscopy adjusted by other covariates is
summarized in Table 5. Having employment or being a
business woman, secondary or higher level of education
attainment, receipt of three or more doses of IPTp-SP, at-
tendance of four or more ANC visits and bed net use were
associated with decreased trend towards odds of periph-
eral malaria in bivariate analysis, although these variables
did not reach statistical significance. Only women deliver-
ing at Katoro rural health centre had a significant trend
towards increased odds of peripheral malaria by
Table 3 Analysis of factors associated with placental parasite density among delivering women
Variable Parasite density Crude OR P-value Adjusted OR P-value
N No. of PD >100/μl, (%) (95% CI) (95% CI)
Maternal age
<20 years 42 22 (52.38) 2.04 (1.00, 4.16) 0.049 1.98 (0.76, 5.17) 0.162
≥20 years 120 42 (35.00) Reference Reference
Health facility
Geita hospital 93 23 (24.73) Reference Reference
Katoro HC 69 41 (59.42) 4.46 (2.27, 8.73) <0.001 5.32 (2.45, 11.57) <0.001
Gravidity
Paucigravidae 94 43 (45.74) 1.89 (0.98, 3.63) 0.058 2.05 (0.85, 4.93) 0.110
Multigravidae 68 21 (30.88) Reference Reference
Level of education
None/Primary 140 61 (43.57) 4.89 (1.38, 17.29) 0.014 3.18 (0.80, 12.55) 0.099
Secondary/Higher 22 3 (13.64) Reference Reference
Occupation
Peasant/livestock 143 61 (42.66) 3.97 (1.11, 14.23) 0.034 2.16 (0.53, 8.82) 0.285
Employed/Business 19 3 (15.79) Reference Reference
Bed net use
No 6 5 (88.33) 8.33 (0.95, 73.13) 0.056 12.88 (1.27, 130.15) 0.030
Yes 152 57 (37.50) Reference Reference
SP receipt
<3 doses 158 64 (40.51) - - - -
≥3 doses 4 0 (0.00)
HC = health centre; OR = odds ratio, PD = parasite density, 95% CI = 95% confidence interval, SP = sulphadoxine-pyrimethamine; Significant p-values are presented
in bold.
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multivariable analysis (AOR = 2.77, p = 0.014).
Uptake of IPTp-SP and placental parasitaemia by
microscopy
As shown in Figure 1, the prevalence of placental malaria
was lowest (15.38%) among women who received three or
more IPTp-SP doses and was highest (43.1%) among those
who did not receive any dose of SP. Placental malaria para-
sitaemia was higher among women aged below 20 years (p
= 0.188) and among paucigravidae (p = 0.084) in bivariate
analysis although the difference was not statistically signifi-
cant. In multivariable analysis (Table 6), adjusted for age,
health facility, gravidity, bed net use and ethnicity; women
who took three or more doses of IPTp-SP had a lower
odds of placental parasitaemia when compared with those
who took less than doses (AOR = 0.31, p = 0.039).
The influence of placental malaria parasitaemia and other
covariates on pre-term delivery
Factors associated with pre-term delivery are shown in
Table 7. In bivariate analysis, the odds of delivering a
pre-term infant was higher among: 1) young women(p = 0.008); 2) delivering at Katoro rural health centre
(p = 0.002); 3) women with positive placental smear
compared to uninfected (p = 0.001) and taking the last
dose of IPTp-SP more than four weeks before delivery
(p = 0.069). In multivariable analysis, being of young
age <20 years (p = 0.029), having placental malaria
(p = 0.002), and taking the last dose of SP more than
four weeks before delivery (p = 0.026) remained signifi-
cantly associated with increased odds of pre-term delivery.
The influence of placental malaria parasitaemia and other
covariates on infant birth weights
The association between placental malaria and infant birth
weight is summarized in Table 8. Mean birth weights were
significantly lower: in infants born by mothers younger than
20 years (2930 ± 414 g) compared to mothers aged 20 years
or older (3271 ± 436 g) (p <0.001), by paucigravidae (3141
± 460 g) compared to multigravida (3289 ± 436 g) (p
<0.001), by women with less than four ANC visits (3141 ±
460 g) compared to four or more visits (3289 ± 428 g),
(p = 0.001), by women with placental parasitaemia (3096 ±
448 g) than that of uninfected counterparts (3254 ± 448 g)
(p <0.001), and preterm birth (2728 ± 503 g) than
Table 4 Analysis of factors associated with malaria in pregnancy by rapid diagnostic test among delivering women
Variable MIP by RDT Crude OR P-value Adjusted OR P-value
N No. RDT-positive (%) (95% CI) (95% CI)
Maternal age
<20 years 97 27 (27.84) 1.87 (1.11, 3.18) 0.020 1.05 (0.54, 2.05) 0.888
≥20 years 334 57 (17.07) Reference Reference
Health facility
Geita hospital 265 36 (13.58) Reference Reference
Katoro HC 166 48 (28.92) 2.59 (1.59, 4.21) <0.001 2.86 (1.69, 4.86) <0.001
Gravidity
Paucigravidae 227 56 (24.67) 2.06 (1.25, 3.39) 0.005 2.37 (1.29, 4.38) 0.006
Multigravidae 204 28 (13.73) Reference Reference
Level of education
None/Primary 360 80 (22.22) 4.79 (1.69, 13.53) 0.003 3.51 (1.19, 10.39) 0.023
Secondary/Higher 71 4 (5.63) Reference Reference
Occupation
Peasant/livestock 370 79 (21.35) 3.04 (1.18, 7.85) 0.021 1.86 (0.68, 5.10) 0.230
Employed/Business 61 5 (8.20) Reference Reference
Bed net use
No 10 4 (40.00) Reference Reference
Yes 403 77 (19.11) 0.35 (0.10, 1.28) 0.115 0.28 (0.07, 1.10) 0.067
SP receipt
<3 doses 405 84 (20.74) - - - -
≥3 doses 26 0 (0.00)
HC = health centre; RDT = rapid diagnostic test, MIP =malaria in pregnancy, OR = odds ratio, 95% CI = 95% confidence interval, SP = sulphadoxine-pyrimethamine;
Significant p-values are presented in bold.
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linear regression analysis (Table 8), maternal age younger
than 20 years (p <0.001), paucigravidae (p = 0.002), women
with placental malaria (p = 0.039), preterm delivery (p <
0.001) and ANC visits less than four (p = 0.001) remained
statistically significantly associated with delivery of infants
with lower mean birth weights. The mean birth weights of
infants born by women who received three or more doses
of IPTp-SP were higher (3311 ± 476 g) than those who re-
ceived less than three doses (3187 ± 452 g); although this
variable did not reach statistical significance (p = 0.713).
Discussion
Uptake of IPTp-SP
In SSA, the effectiveness of IPTp-SP in prevention of
malaria-related adverse pregnancy outcomes is well do-
cumented [13-15,21]. However, the coverage of recom-
mended doses of IPTp-SP in SSA is still very low [16]. In
the present study, the uptake of at least one and two doses
of SP were consistent with national estimates from the
2011–12 Tanzania HIV/AIDS and Malaria Indicator
Survey report of 60% and 32%, respectively [18]. However,the uptake of at least two doses of SP observed in the
present study was lower than 35% reported previously in
the same study area [28], reflecting the inconsistency of
drug supply at the time of survey in the given area. The up-
take of the recommended three doses of IPTp-SP has
never been evaluated in Tanzania. The uptake of at least
three doses of IPTp-SP in the present study was very low.
The uptake of IPTp-SP in the present study is far below
the Roll Back Malaria (RBM) target for all pregnant
women living in areas with stable transmission in SSA to
receive IPTp-SP by the end of 2015 [29].
Receipt of ≥ three doses of IPTp-SP in the present
study was higher among women making ≥ four ANC
clinic visits compared to women making fewer visits and
among women residing in rural areas. These findings are
consistent with that of Exavery et al. conducted in six
selected districts of Tanzania [28], in Ghana by
Hommerich et al. [15], in rural Burkina Faso by Gies et al.
[14], and in Mali by Hill et al. [30]. ANC attendance is the
entry point for receiving IPTp-SP; the more visits the
woman attends the higher the number of SP she will re-
ceive. The ANC attendance of at least four visits was 36%
Table 5 Analysis of factors associated with peripheral malaria by microscopy among delivering women
Variable Peripheral malaria Crude OR P-value Adjusted OR P-value
N No. peripheral malaria positive (%) (95% CI) (95% CI)
Maternal age
<20 years 97 33 (34.02) 130 (0.80, 2.10) 0.291 1.28 (0.76, 2.14) 0.350
≥20 years 334 95 (28.44) Reference Reference
Health facility
Geita hospital 265 67 (25.28) Reference Reference
Katoro HC 166 61 (36.75) 1.72 (1.13, 2.61) 0.012 1.76 (1.12, 2.77) 0.014
Level of education
None/Primary 360 113 (31.39) 1.71 (0.93, 3.15) 0.086 1.29 (0.66, 2.53) 0.458
Secondary/Higher 71 15 (21.13) Reference Reference
Occupation
Peasant/livestock 370 116 (31.35) 1.86 (0.96, 3.64) 0.068 1.43 (0.69, 2.98) 0.340
Employed/business 61 12 (19.67) Reference Reference
SP receipt
<3 doses 405 124 (30.62) Reference Reference
≥3 doses 26 4 (15.38) 0.41 (0.14, 1.22) 0.110 0.68 (0.22, 2.14) 0.489
ANC visits
1-3 276 88 (31.88) 1.35 (0.87, 2.09) 0.186 1.32 (0.83, 2.12) 0.243
≥4 155 40 (25.81) Reference Reference
Bed net use
No 10 5 (50.00) Reference Reference
Yes 403 118 (29.28) 0.41 (0.12, 1.45) 0.169 0.39 (0.12, 1.39) 0.164
ANC = antenatal care; OR = odds ratio, 95% CI = 95% confidence interval, SP = sulphadoxine-pyrimethamine; Significant p-values are presented in bold.
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nancy was only 6% in this study, suggesting missed oppor-
tunities when women attended clinics but were not
given IPTp-SP. The high ANC attendance rate with low
uptake of IPTp can be explained in part by periodic
shortage of SP in the health facility, poor adherence by
health providers to provision of IPTp-SP and women’s
negative attitudes towards the use the drug during preg-
nancy [30,31].
Prevalence of placental malaria
The prevalence of malaria infection using RDT, peripheral
and placental smears was 19.49%, 29.70% and 37.60% re-
spectively. The sensitivity of RDT over microscopy in
diagnosis of malaria in pregnancy was very low (<40%).
The difference can be explained, in part, that the perfor-
mance of RDT depends on the level parasitaemia and the
tests are more sensitive when parasite densities >100 para-
sites/μL [32]. In the present study, over half of wo-
men with asymptomatic parasitaemia had low parasite
density <100 parasites/μL. The finding is similar to an
observational study conducted in Nigeria whereby SD
Bioline RDT sensitivity was reported to be 47% amongasymptomatic children [33] but contrary to a report from
Burkina Faso where RDT had sensitivity of 89% [34]. The
prevalence of malaria in pregnancy by RDTs was consist-
ent with a recent report from Zambia by Tan et al. where
19.77% [35] Plasmodium falciparum infection was ob-
served in 94.05% of delivering women as either mixed in-
fection (32.14%) or as a mono-infection (61.91%). This is
consistent with previous reports that falciparum malaria
was the predominant infection observed among pregnant
women [3,9]. The prevalence of placental malaria by thick
film smear was high (37.6%) in this study. This prevalence
of placental malaria can be attributed, in part, to increased
transmission intensity with elevated re-infection rates
between the last dose of SP and delivery, low uptake of
IPTp-SP and that the study was conducted during the end
of rainy season where transmission is at its highest peak
[14]. The prevalence of placental malaria by microscopy is
similar to those reported in Cameroon (33.7%) and Ghana
(38.6%) [36,37] but was higher than previously reported in
Uganda (17.5%) and among Cameroonian parturient
women (25.5%) [38,39]. However, the prevalence of pla-
cental malaria in this study is lower than that reported by





























No SP 1 Dose SP 2 Doses SP 3 + Doses SP
Figure 1 Prevalence of placental parasitaemia by frequency of sulphadoxine-pyrimethamine doses among 431 delivering women. The
prevalence of placental parasitaemia was lowest among women who received three or more doses of SP during pregnancy and was highest
among expectant women who did not receive any dose.
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valence of placental malaria across the regions can be ex-
plained by geographical variations in malaria transmission
intensities, seasonality, differences in the characteristics of
study participants, coverage of preventive measures, and
study designs.
IPTp-SP use and malaria in pregnancy
In Geita district, uptake of three or more doses of IPTp-SP
was a perfect predictor of negative malaria in pregnancy
using RDT in bivariate analysis. Moreover, receipt of three
or more doses of SP was associated with significantly
reduction of placental parasitaemia, which supports the
recent policy change from two to three or more doses of
IPTp-SP in Tanzania. The superiority of three or more
over less than three doses of SP in reduction of placental
malaria and birth outcomes is consistent with a recent
clinical trial conducted in Mali [13]. The significant pro-
tection of SP against placental malaria is not surprising in
an area with moderate to high SP P. falciparum resistance
[41].This supports the WHO recommendation to con-
tinue use of SP as IPTp even in areas with high levels ofSP resistance [42]. In north-eastern Tanzania where there
is high SP resistance, Harrington et al. and Minja et al. re-
ported loss of efficacy of SP as IPTp and exacerbation of
adverse birth outcomes [43,44]. However, receipt of ≥
three doses of IPTp-SP was not associated with reduced
odds of peripheral malaria in the present study. The lack
of association could be explained, in part, by the fact that
a small proportion of women took the recommended
three or more doses of SP during pregnancy and that this
may have reduced the power to produce an effect.
Placental malaria and pre-term delivery
The number of doses of IPTp-SP taken was not asso-
ciated with reduced risk of pre-term delivery. However,
women who received the last dose of IPTp-SP within
four weeks of delivery had a 62% odds reduction of de-
livering pre-term infants. This is not surprising as the
protection period of IPTp-SP is around four weeks.
The presence of placental parasitaemia was associated
with a significant trend towards increased odds of pre-
term delivery. This finding concurs with those reported
previously across SSA where malaria is highly endemic
Table 6 Analysis of factors associated with placental malaria by microscopy among delivering women
Variable Placental malaria (PM) Crude OR P-value Adjusted OR P-value
N No. PM positive (%) (95% CI) (95% CI)
Maternal Age
<20 years 97 42 (43.30) 1.36 (0.86, 2.16) 0.188 1.08 (0.62, 1.89 0.790
≥20 years 334 120 (35.93) Reference Reference
Ethnicity
Sukuma/Zinza 309 122 (39.48) 1.34 (0.86, 2.08) 0.197 1.18 (0.74, 1.89) 0.489
Other Tribes 122 40 (32.79 Reference Reference
Health facility
Geita hospital 265 93 (35.09) Reference Reference
Katoro HC 166 69 (41.57) 1.32 (0.88, 1.96) 0.177 1.29 (0.84, 1.98) 0.239
Gravidity
Paucigravidae 227 94 (41.41) 1.41 (0.95, 2.09) 0.084 1.43 (0.89, 2.30) 0.135
Multigravidae 204 68 (33.33) Reference Reference
SP receipt
<3 doses 405 158 (39.01) Reference Reference
≥3 doses 26 4 (15.38) 0.28 (0.10, 0.84) 0.023 0.31 (0.10, 0.94) 0.039
Bed net use
No 10 6 (60.00) 2.48 (0.69, 8.92) 0.165 2.53 (0.69, 9.26) 0.159
Yes 403 152 (37.72) Reference Reference
HC = health centre; OR = odds ratio, 95% CI = 95% confidence interval, PM = placental malaria; SP = sulphadoxine-pyrimethamine; Significant p-values are
presented in bold.
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was not associated with pre-term delivery [46]. The pa-
thophysiology of placental parasitaemia and pre-term
delivery is uncertain. However, malaria-infected placen-
tas often release inflammatory immune responses, such
as antibodies, cytokines and macrophages, which may be
responsible for early uterine stimulation initiating labour
[3]. These mechanisms are thought to result in pre-term
labour.
Placental malaria and infant birth weight
The prevalence of LBW in this study was very low
(2.32%) and the overall mean birth weight was high
(3194.20 ± 2187 g). The uptake of three or more doses of
SP was not associated with a significant increase in
mean birth weight of new-borns. The lack of association
in this study could be explained, in part, by the low up-
take of optimal doses of SP and high mean birth weight.
In addition, the small sample size of the current study
may not provide the power needed to detect the effect
on birth weight.
Infants born to women who attended ANC clinics four
or more times were on average 128 g heavier than in-
fants of women who had attended ANC clinics less than
three times. The association between ANC clinic visits
and mean birth weight can be explained by the fact thatmore visits are associated with the receipt of more SP
when readily available, and women supplemented with
haematinics, counselled on nutrition during pregnancy,
all of which are associated with improved birth weight.
Moreover, infants born to young mothers and those
born prematurely were 193 g and 128 g lighter than
those born to older mothers and those born at term.
Delivery of lower birth weight infants among young
mothers can be explained by the fact that this age group is
susceptible to malaria infection owing to inadequate
pregnancy-associated immunity. For example, anticytoad-
herent antibodies that inhibit adhesion of P. falciparum to
chondroitin sulphate A (CSA) is under-developed among
first-time young pregnant women, compared to older
non-first-time mothers with adequate immunity as a re-
sult of repeated exposure to malaria parasites [46]. Placen-
tal malaria was not associated with delivery of LBW owing
to low prevalence of LBW in the current study that could
not provide sufficient power to detect any potential asso-
ciations. The low prevalence of LBW despite high preva-
lence of placental malaria can be explained by fact that
there could be other causes of intrauterine foetal growth
such as maternal malnutrition, maternal/foetal constitu-
tional factors and other environmental non-infectious fac-
tors [47]. However, analysing birth weights as continuous
variable, women with placental parasitaemia were more
Table 7 Secondary analysis of factors associated with pre-term delivery among delivering women
Variable Pre-term delivery§ Crude OR P-value Adjusted OR P-value
N No. PTD (%) (95% CI) (95% CI)
Maternal age
<20 years 97 21 (21.65) 2.22 (1.23, 4.01) 0.008 2.92 (1.12, 7.65) 0.029
≥20 years 334 37 (11.08) Reference Reference
Health facility
Geita hospital 265 25 (9.43) Reference Reference
Katoro HC 166 33 (19.88) 2.38 (1.36, 4.18) 0.002 2.02 (0.65, 6.35) 0.227
Peripheral malaria
Positive 128 19 (14.84) 1.18 (0.65, 2.13) 0.584 0.36 (0.11, 1.10) 0.073
Negative 303 39 (12.87) Reference Reference
Level of education
None/Primary 360 53 (14.72) 2.28 (0.88, 5.92) 0.091 1.69 (0.45, 6.33) 0.439
Secondary/Higher 71 5 (7.04) Reference Reference
Placental malaria
Positive 162 33 (20.37) 2.50 (1.42, 4.38) 0.001 4.67 (1.74, 12.58) 0.002
Negative 269 25 (9.25) Reference Reference
MIP by RDT
Positive 84 16 (19.05) 1.71 (0.91, 3.22) 0.097 2.13 (0.69, 6.59) 0.188
Negative 347 42 (12.10) Reference Reference
SP receipt
<3 doses 405 55 (13.58) Reference Reference
≥3 doses 26 3 (11.54) 0.83 (0.24, 2.86) 0.768 0.55 (0.13, 2.33) 0.416
Last SP time lapse
≤4 weeks 26 14 (53.85) 0.47 (0.21, 1.06) 0.069 0.38 (0.15, 0.97) 0.042
>4 weeks 238 170 (71.43) Reference Reference
HC = health centre; RDT = rapid diagnostic test, MIP =malaria in pregnancy, PTD = pre-term delivery, § = Assessed by first day of last menstrual period or by
New Ballard Score; Significant p-values are presented in bold.
Mpogoro et al. Malaria Journal 2014, 13:455 Page 11 of 14
http://www.malariajournal.com/content/13/1/455likely to deliver lower birth weight infants than uninfected
women. The association between placental parasitaemia
and low mean birth weight in this study is consistent with
previous reports [3,5,9,45,48]. The delivery of LBW can be
caused by pre-term delivery or by placental malaria se-
questration causing intrauterine growth restriction (IUGR)
[9,48]. Foetal growth restriction as a result of placental
malaria sequestration is mediated by accumulation of in-
fected erythrocytes into the maternal placental intervillous
spaces that trigger chronic inflammatory responses lead-
ing to placental insufficiency [2,48].
Limitations
This study was an analytical, cross-sectional study. Al-
though efforts were made to control for confounders at
the design and analyses stages, unidentified confounders
may still have affected the observations. In addition, it is
possible that not the entire dose of SP given to women
was actually taken, as the receipt of SP was self-reportedand some women did not consume SP as a directly
observed therapy. There may have been a possibility of
over-estimating IPTp-SP use in the study, as some par-
ticipants may have tried to please the interviewer. A sig-
nificant number of women who deliver outside health
facilities in Tanzania may have had more adverse birth
outcomes. However, this study had the limitation of
recruiting study participants at delivery units. Therefore,
this study was not representative of the wider population
in north-western Tanzania. The lack of association bet-
ween the uptake of > three doses of IPTp-SP and birth
outcomes (pre-term delivery and LBW) could be attri-
buted to the small sample size and the proportion of
women who took the recommended dose.
Conclusions
Placental parasitaemia is common in Geita district and
is likely to be associated with pre-term delivery. Uptake
of IPTp with SP is very low among pregnant women
Table 8 Secondary analysis of factors associated with low birth weight delivery among delivering women
Variable Mean birth
weight (SD) g
Coefficient P-value Coefficient P-value
(95% CI) (95% CI)
Maternal age
<20 years 2,930 (414) −341 (−439, −243) <0.001 −193 (−297, −90) < 0.001
≥20 years 3,271 (436) Reference Reference
Gravidity
Paucigravidae 3,141 (460) −243 (−326, −160) <0.001 −134 (−220, −48) 0.002
Multigravidae 3,289 (428) Reference Reference
ANC visits
1-3 visits 3,141 (460) −148 (−237, −60) 0.001 −128 (−206, −50) 0.001
≥4 visits 3,289 (428) Reference 1
Placental malaria
Positive 3,096 (448) −158 (−245, −70) <0.001 −82 (−160, −4) 0.039
Negative 3,254 (448) Reference 1
SP receipt
<3 doses 3,187 (452) −125 (−305, 55) 0.174 30 (−129, 188) 0.713
≥3 doses 3,311 (476) Reference Reference
Gestational age
Pre-term delivery 2,728 (503) −539 (−654, −424) <0.001 −479 (−589, −369) <0.001
Term delivery 3,267 (400) Reference Reference
ANC = antenatal care; SD = standard deviation, 95%CI = 95% confidence interval, Significant p-values are presented in bold.
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http://www.malariajournal.com/content/13/1/455attending ANC clinics in public health facilities of Geita
district. However, the uptake of three or more doses of
IPTp-SP in this area with highly intense malaria trans-
mission is associated with reduction of placental malaria.
Effort is needed to scale-up the uptake of optimal doses
of IPTp-SP especially in peri-urban areas of Geita dis-
trict. A longitudinal study may be required to evaluate
the relationship between the uptake of recommended
doses of IPTp-SP and birth outcomes in this area. Given
substantial utilization of ANC in contrast to the low up-
take of IPTp-SP in this population, qualitative research
studies are needed to determine any underlying barriers
of utilization of intermittent preventive treatment of
malaria with SP during pregnancy.Abbreviations
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